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The autosomal recessive immunodeficiency-centromeric instability-facial anomalies syndrome (ICF) is characterized
by immunodeficiency, developmental delay, and facial anomalies. ICF2, caused by biallelic ZBTB24 gene mutations,
is acknowledged primarily as an isolated B-cell defect. Here, we extend the phenotype spectrum by describing, in
particular, for the first time the development of a combined immune defect throughout the disease course as well
as putative autoimmune phenomena such as granulomatous hepatitis and nephritis. We also demonstrate impaired
cell-proliferation and increased cell death of immune and non-immune cells as well as data suggesting a chromosome
separation defect in addition to the known chromosome condensation defect.
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GranulomasLetter to the editor
The autosomal recessive immunodeficiency-centromeric
instability-facial anomalies (ICF) syndrome is character-
ized by immunodeficiency, intellectual deficit, and facial
dysmorphism [1]. ICF 1 and 2 are caused by biallelic mu-
tations in the DNA methyltransferase 3B gene DNMT3B
(MIM*602900, [2,3]) and in the zinc-finger-and BTB-
domain containing 24 gene ZBTB24 (MIM*614064, [4]),
respectively. For ICF2, 16 patients from 13 families have
been reported (Additional file 1: Table S1) [4-13]. ICF
is considered primarily as a humoral immunodeficiency
disease; however, this does not explain the high rate of
opportunistic infections. Recently, an additional intrin-
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article, unless otherwise stated.lymphocyte proliferation defect described in individual
patients with ICF1 and ICF2 [5,8,9]. Mechanisms
underlying the neurological phenotype of ICF remain to
be elucidated. Here, we report the development of a com-
bined immunodeficiency in a patient with ICF2 with age
and demonstrate pathomechanisms that may contribute
to the immunological and non-immunological phenotype.
The index patient was born hypotrophic at term without
complications as the first child of non-consanguineous
healthy, Caucasian parents of German descent after an un-
eventful pregnancy. She showed multiple facial anomalies,
clubbing of fingers and toes, and fused teeth (Figure 1A).
Language and motor development appeared initially
normal, but intellectual disability became apparent by
the second year of life. Her brain morphology was nor-
mal on MRI at 4 years-of-age, apart from a pineal cyst.
Growth stagnated at 4.5 years-of-age with height,
weight, and head circumference of 101 cm (-4.79 SD),
15 kg (-2.51 SD), and 50 cm (-1.2 SD) at 9 years-of-age
(Figure 1A). Bone age was delayed by 4 years at 8 years-
of-age, and growth hormone levels were undetectable but
could be stimulated.ntral Ltd. This is an Open Access article distributed under the terms of the
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, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 Phenotype and genotype of index patient with ZBTB24 mutation. (A) Clinical signs at 8 years-of-age: protruding abdomen due to
organomegaly in the otherwise underweight girl of short statue, facial dysmorphism (hypertelorism, epicanthal folds, flat nasal bridge, hypertelorism,
slight ptosis, prominent forehead). Large teeth result from a fusion of first molar with the incisors. Fingers and toes showed clubbing. Failure to thrive
evident in a percentile height-weight-curve. (B) Pseudo-Pelger-Huët anomaly of neutrophils (Diff-Quick staining, 100x, n = 400 cells, Student’s t-test,
p < 0.0001). (C) Site of homozygous ZBTB24 mutation c.1222 T > G (protein domains: BTB, bric-a-bric, tramtrack, broad complex domain; AT hook,
DNA-binding domain with a preference for A/T rich regions, Zinc finger C2H2). (D) Electropherogram traces in patient and heterozygous parents
(NM_014797) indicating mutation confirmed by Sanger sequencing. Unaltered ZBTB24 mRNA levels and product size is depicted in Additional file 8:
Figure S2. (E) Highly conserved amino acids affected by the inherited homozygous mutation (p.C408G). (F) Spontaneous undercondensation of
constitutive heterochromatin of chromosomes 1q, 16q, and (to a lesser extent) 9q.
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infections of the upper airways beginning at 9 months,
a pneumonia at 2.5 years-of-age (Enterobacter cloacae),
recurrent and protracted diarrhoea (enteropathogenic
E. coli), and a prolonged skin infection (Streptococcus
pyogenes). At 3 years-of-age, a ‘common variable im-
munodeficiency (CVID)’ was diagnosed based on the
global reduction of immunoglobulins and the lack of
antibodies against recall antigens despite regular vac-
cination (Additional file 2: Table S2), subcutaneous IgG
substitution was started, and the patient subsequently
remained free of invasive infections. Further analysis re-
vealed microcytic hypochrome anemia with anisocytosis,
normal global T-/B-cell counts, intermittent neutropenia,
and Pseudo-Pelger-Huët anomaly of neutrophilic granulo-
cytes suggestive of a terminal neutrophil differentiation
defect (Additional file 3: Table S3, Figure 1B). The pa-
tient (blood group 0) lacked isohemagglutinins against
blood group substances A and B. Starting at 3.5 years-
of-age, CD8+ T-cells were elevated and CD4+ T-cells
dropped, leading to a profoundly reduced CD4/CD8
ratio (Additional file 3: Table S3). In parallel to the
CD8+ T-cell expansion, relative numbers of CD4 +
CD45RA + naïve T-cells declined, resulting in a relative
CD4 + CD45R0+ T-cell increase (Additional file 3:
Table S3). The TCRVβ-repertoire was normal, and bone
marrow analysis excluded myelodysplasia. Lymphocyte
proliferation was strongly reduced upon stimulation with
mitogens, CD3-directed antibody, and tetanus toxoid des-
pite appropriate tetanus vaccination (Additional file 4:
Table S4). Initially normal NK-cell numbers declined grad-
ually, and diminished NK-cell mediated lysis could be re-
stored only partly through IL-2 addition (Additional file 3:
Table S3, Additional file 5: Table S5).
Massive hepatosplenomegaly developed by 3 years that
progressed to liver cirrhosis by 9 years-of-age. Repeated
liver biopsies at 4.5 and 8.5 years-of-age revealed chron-
ically active interface hepatitis with periportal lymphoid
infiltrates and fibrosis (Additional file 6: Figure S1); no in-
fection with hepatotopic viridae (cytomegalovirus, Epstein
Barr virus, herpes viridae (HSV1, HSV2, HHV6, HHV7),
hepatitis viridae A-E, adenovirus, enterovirus, parvovirus
B19, hantavirus, and human polyoma virus BK-virus) ormycobacteriae was detected (Additional file 7: Table S6).
Compensated renal insufficiency at 4.5 years-of-age
prompted a kidney biopsy that revealed interstitial
granulomatous nephritis (Additional file 6: Figure S1),
but no evidence of mycobacterial infection through
PCR, staining procedure, and direct culture. A four-
week course of immunosuppressive treatment with
corticosteroids and azathioprine was not successful in
normalizing liver enzymes or kidney function. The increase
of CD8+ T-cells is likely an autoimmune phenomenon
non-responsive to standard immunosuppressive treatment;
however, an ongoing, non-identified chronic infection can-
not be ruled out. The increase of IgA, IgM, and IgG later
in life can be an effect secondary to progressive liver
cirrhosis. The patient is still under IgG-substitution,
and protein-electrophoresis revealed no indication of
an increase of mono- or oligoclonal immunoglobulins
(data not shown).
By whole exome sequencing, we identified the homozy-
gous missense mutation c.1222 T >G of the ZBTB24 gene
(NM_014797) in the index patient inherited from the
healthy parents (Figure 1C). This previously described mu-
tation alters evolutionarily conserved amino acids in a highly
conserved zinc finger domain (p.C408G; Figure 1D,E,
Additional file 1: Table S1). Patients with the c.1222 T >G
mutation show a variable phenotype, arguing against a
clear genotype-phenotype correlation and for a residual
activity of mutant ZBTB24. In line with this, ZBTB24
mRNA levels did not differ significantly between patient
and control (Additional file 8: Figure S2). Chromosome
metaphase preparations revealed increased rates of
undercondensated juxta-centromeric chromosomes 1q,
16q, and less frequent of 9q regions, characteristic for
ICF2 (Figure 1F). This further increased upon exposure
of cultures to 5-azacytidine (DNA methylation interfer-
ing agent), eventually resulting in chromosome instabil-
ity (data not shown). Because ZBTB24 not only impacts
on immune cells, we examined patient fibroblasts and
detected significantly reduced proliferation, increased
apoptosis and discrete spindle defects (broader and un-
focused microtubule poles; Figure 2A-D, Additional file 9:
Figure S3). In mutant cells, centrosomal CDK5RAP2 was
strongly reduced, while centrosomal y-tubulin staining
Figure 2 (See legend on next page.)
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Figure 2 Cellular defects in patient fibroblasts and lymphoblastoid cells, reproduced in HEK cells through siRNA and expression of
mutant ZBTB24. (A) Reduced cell viability (n = 8 per time period, Student’s t-test), (B) reduced proliferation (n = 8, 36 h after plating, Student’s
t-test), and (C) increased apoptosis of ZBTB24 mutant fibroblasts (activated caspase 3/7 per cell viability; n = 8, Student’s t-test). (D) Abnormal
spindle (α-tubulin) formation with increase of slightly broader, unfocused microtubules poles (n = 100 metaphase LCLs, Student’s t-test, view
Additional file 9: Figures S3 for further images throughout the cell cycle and specifically in metaphase cells) and (E, F) strongly reduced fluorescence
signals of centrosomal marker CDK5RAP2 (but not γ-tubulin) in patient lyphoblastoid cells (n = 105 metaphase cells, Student’s t-test); total γ-tubulin
levels were unaltered (n = 3, Student’s t-test). Scale bar 5 μm. View Additional file 10: Figures S4 for further images throughout the cell cycle and
specifically in metaphase cells. (G) Reduced cell viability (n = 8 per time period, One-way ANOVA) and (H) mitotic spindles defect in HEK cells
expressing mutant (c.1222 T > G) ZBTB24. Abnormal spindle formation with slightly broader, unfocused microtubule poles in mutant cells. Scale bar
5 μm. View Additional file 11: Figure S5 for further images throughout the cell cycle, qPCR and Western blot results. (I) ZBTB24 mRNA downregulation
in HEK through siRNA (qPCR, Student’s t-test) causes (J) reduced cell culture growth (n = 3 per group per time period; Student’s t-test). ns = not
significant, *p < 0.05, **p < 0.01, ***p < 0.001.
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Additional file 10: Figure S4). The mechanisms underlying
the reduction in CDK5RAP2, which is associated with
stem cell proliferation and microcephaly with intellectual
deficit [14], may be involved in the pathogenesis of the
neurological phenotype of ICF.
We further mimicked the situation in the patient
through ZBTB24 siRNA knockdown experiments in
HEK293 cells and over-expressed mutant and wild-type
ZBTB24 in these cells (Figure 2G-J). Cell culture growth
was significantly reduced when mutant, but not wild-type,
ZBTB24 was expressed, and both discrete spindle defects
and an abnormal centrosomal CDK5RAP2 staining were
observed (Figure 2G,H, Additional file 11: Figure S5).
Down-regulation of ZBTB24 through siRNA similarly re-
duced cell culture growth (Figure 2 I,J).
The novelty of our report lies in the description of the
development of a combined immunodeficiency (CID) with
age in ICF2, a feature that may be missed if immuno-
logical work-up is only performed once at a young age.
We also highlight findings consistent with autoimmune
phenomena (hepatitis, nephritis), which are commonly
seen in CID but not acknowledged for ICF [15]. Finally,
we report for the first time a defect in cell survival and
proliferation in immune and non-immune cells. This may
constitute a disease mechanism common for both the
non-immunological and immunological features of ICF2,
the latter presenting as CID. The clinical course of the
index patient and of previously reported patients calls for
consideration of early stem cell transplantation as an op-
tion in patients with ICF.
Please see Additional file 12: Materials and Methods
for details on materials and methods.Consent statement
Written informed consent was obtained from the patient’s
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available for review by the Editor-in-Chief of this journal.Additional files
Additional file 1: Table S1. Genotype and phenotype of all published
ICF2 patients.
Additional file 2: Table S2. Immunoglobulin levels and antibody titers.
Additional file 3: Table S3. Blood counts and lymphocyte
subpopulations.
Additional file 4: Table S4. Lymphocyte proliferation assays.
Additional file 5: Table S5. NK-cell cytotoxicity assay. Percentages of
lysed K562 cells at different effector:target ratios with and without
supplementation with IL-2 at the age of 4 years are shown.
Additional file 6: Figure S1. Histological biopsy results. (A) Liver biopsy
at the age of 4,5 years. Portal lymphocytic infiltrates and interface hepatitis.
(B) Liver biopsy at the age of 8,5 years. Porto-portal bridging. (C) Kidney
biopsy at the age of 4,5 years. Normal glomerula. (D) Kidney biopsy at the
age of 4,5 years showed multifocal inflammatory infiltrates in cortex and
medulla of the tubulo-interstitium and a multinuclear giant cell.
Additional file 7: Table S6. Pathogens excluded to cause hepatitis.
Additional file 8: Figure S2. ZBT24 mRNA levels in controls and
fibroblasts. (A) RT-PCR of ZBTB24 in fibroblasts of controls and the patient.
(B) Quantitative RT-PCR of ZBTB24 in fibroblasts of a control cell line and
the patient.
Additional file 9: Figure S3. Mitotic spindles defect in ZBTB24 mutant
patient cells. Subcellular localization of the spindle marker α-tubulin
(green) and the centrosome marker CDK5RAP2 (red) of immortalized
lymphocytes of (A) control and (B) ICF2 patient throughout the cell cycle.
DNA was stained with DAPI (blue). Patient cells have abnormal spindle
formation with an increase of slightly broader, unfocused microtubules
poles. The fluorescence signals of the centrosomal marker CDK5RAP2 are
strongly reduced in patient cells when compared to control cells.
Immunofluorescence, scale bar 5 μm.
Additional file 10: Figure S4. Abnormal CDK5RAP2 and normal γ-tubulin
staining of centrosomes in ZBTB24 mutant patient cells. (A) Subcellular
localization of the centrosome marker CDK5RAP2 (red) in the metaphase of
immortalized lymphocytes of control and ICF2 patient. DNA was stained
with DAPI (blue). Centrosomal CDK5RAP2 is strongly reduced in ZBTB24
mutant lymphocytes when compared to controls. (B) Subcellular
localization of the centrosome marker γ-tubulin (green) in the metaphase of
immortalized lymphocytes of control and ICF2 patient. DNA was stained with
DAPI (blue). No strong difference between the γ-tubulin immunostaining of
control and ICF2 patient Immunofluorescence, scale bar 5 μm.
Additional file 11: Figure S5. Mimicking ICF2 in HEK cells. (A) ZBTB24
mRNA levels and in mock-transfected HEK cells (“control”), HEK cells
transfected with HA-tagged normal ZBTB24 or mutant c.1222 T > G
ZBTB24, assessed by qPCR. (B) Western-Blot of ZBTB24 of protein extracts
from similarly transfected HEK cells using antibodies directed against
HA-tag and against ZBTB24 (reference proteins GAPDH and actin). (C)
Subcellular localization of the centrosome marker γ-tubulin (green) and
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mock-transfected HEK cells (“control”) and HEK cells transfected with
mutant c.1222 T > G ZBTB24.
Additional file 12: Materials and Methods.
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